Bharat Biotech announced on Friday that it has terminated its Memorandum of Understanding with Precisa Medicamentos and Envixia Pharmaceuticals LLC for its COVID-19 immunization Covaxin for the Brazilian market. The agreement was terminated when a deal with the Brazilian government for the delivery of 20 million doses of the vaccines faced criticism and prompted an inquiry by Brazilian regulators.
Precisa Medicamentos is Bharat Biotech’s Brazilian partner, assisting, guiding, and supporting the company with regulatory filings, licensing, sales, coverage, and the performance of phase III clinical studies, among other things.
According to the company, Bharat Biotech is pursuing licences in numerous nations based on the legal criteria of each country.
Discussion about this post